Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6807-6820

  Svingen, Phyllis A ^a   Loegering, David ^a   Rodriquez, Joe ^b   Meng, Xue Wei ^a   Mesner Jr , Peter W ^a,f   Holbeck, Susan ^d   Monks, Anne ^c   Krajewski, Stan ^e   Scudiero, Dominic A ^c   Sausville, Edward A ^d   Reed, John C ^e   Lazebnik, Yuri A ^b   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e BURNHAM INSTITUTE   (United States)

^f UNIVERSITY OF WISCONSIN WHITEWATER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; FLUOROURACIL; MELPHALAN; PACLITAXEL; POLYPEPTIDE; PROCASPASE 2; PROCASPASE 3; PROCASPASE 6; PROCASPASE 7; PROCASPASE 8; PROCASPASE 9; SULFORHODAMINE B; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL TYPE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG SENSITIVITY; GENE DELETION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CASPASES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOBLOTTING; NEOPLASMS; PROTEINS; TUMOR CELLS, CULTURED;

EID: 6044273762     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0778-02     Document Type: Article

References (114)

1. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997;89:1845-53.
2. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
3. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-9.
4. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001;11:S22-6.
5. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
6. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science (Wash DC) 1994;266:807-10.
7. Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995;86:1148-58.
8. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin Cancer Res 1996;2:623-33.
9. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997;90:3118-29.
10. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis. A link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
11. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22:7414-30.
12. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science (Wash DC) 1998;281:1312-6.
13. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
14. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
15. Bratton SB, MacFarlane M, Cain K, Cohen GM. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res 2000;256:27-33.
16. Creagh EM, Martin SJ. Caspases: cellular demolition experts. Biochem Soc Trans 2001;29:696-702.
17. Salvesen GS, Dixit VM. Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 1999;96:10964-7.
18. Kischkel FC, Lawrence DA, Tinel A, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001;276:46639-46.
19. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 2001;98:13884-8.
20. Ruchaud S, Korfali N, Villa P, et al. Caspase-6 gene knockout reveals a role for lamin a cleavage in apoptotic chromatin condensation. EMBO J 2002;21:1967-77.
21. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science (Wash DC) 2002;297:1352-4.
22. Marsden VS, O'Connor L, O'Reilly LA, et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature (Lond) 2002;419:634-7.
23. Krammer PH. CD95's deadly mission in the immune system. Nature (Lond) 2000;407:789-95.
24. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
25. Peter ME. The TRAIL DISCussion: it is FADD and caspase-8! Cell Death Differ 2000;7:759-60.
26. Stennicke HR, Jurgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998;273:27084-90.
27. Huang DCS, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000;103:839-42.
28. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
29. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-19.
30. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000;10:369-77.
31. Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev 1999;13:3179-84.
32. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. Three-dimensional structure of the apoptosome. Implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002;9:423-32.
33. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell 2003;11:529-41.
34. Yeh W-C, de la Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science (Wash DC) 1998;279:1954-8.
35. Varfolomeev EE, Schuchmann M, Luria V, et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apol, and DR3 and is lethal prenatally. Immunity 1998;9:267-76.
36. Yoshida H, Kong Y-Y, Yoshida R, et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998;94:739-50.
37. Kuida K, Haydar TF, Kuan C-Y, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998;94:325-37.
38. Hakem R, Hakem A, Duncan GS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998;94:339-52.
39. Li K, Li Y, Shelton JM, et al. Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis. Cell 2000;101:389-99.
40. Tillman DM, Petak I, Houghton JA. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999;5:425-30.
41. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res 2001;61:243-8.
42. Ito Y, Pandey P, Place A, et al. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 2000;11:261-7.
43. Pedersen IM, Kitada S, Schimmer A, et al. The triterpenoid CDDO induces apoptosis in refractory CLL B Cells. Blood 2002;100:2965-72.
44. Kalli KR, Devine KE, Cabot MC, et al. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Mol Pharmacol 2003;64:1434-43.
45. Meng XW, Chandra J, Loegering D, et al. Central role of FADD in apoptosis induction by the mitogen activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cell lines in vitro. J Biol Chem 2003;278:47336-9.
46. Micheau O, Solary E, Hammann A, Dimanche-Boitrel M-T. Fas ligand-independent, FADD-mediated action of the Fas death pathway by anticancer drugs. J Biol Chem 1999;274:7987-92.
47. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 2001;20:1852-9.
48. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
49. Faleiro L, Lazebnik Y. Caspases disrupt the nuclear-cytoplasmic barrier. J Cell Biol 2000;151:951-9.
50. Yang, X-H, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001;61:348-54.
51. Kottke TJ, Blajeski AL, Meng X, et al. Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J Biol Chem 2002;277:804-15.
52. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem and Biophys Res Commun 1999;262:381-7.
53. Shivapurkar N, Toyooka S, Eby MT, et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 2002;1:65-9.
54. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-35.
55. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of Caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-9.
56. Eggert A, Grotzer MA, Zuzak TJ, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001;61:1314-9.
57. Grotzer MA, Eggert A, Zuzak TJ, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000;19:4604-10.
58. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (Lond) 2001;409:207-11.
59. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998;92:3090-7.
60. Faderal S, Thall PF, Kantarjian HM, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res 1999;12:4041-7.
61. Svingen PA, Karp JE, Krajewski S, et al. Evaluation of the prognostic significance of Apaf-1 and caspases -2, -3, -7, -8 and -9 in acute leukemia. Blood 2000;96:3922-31.
62. Nakagawara A, Nakamura Y, Ikeda H, et al. High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res 1997;57:4578-84.
63. Hsia JY, Chen CY, Chen JT, et al. Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol 2003;29:44-8.
64. Kurabayashi A, Furihata M, Matsumoto M, Ohtsuki Y, Sasaguri S, Ogoshi S. Expression of Bax and apoptosis-related proteins in human esophageal squamous cell carcinoma including dysplasia. Mod Pathol 2001;14:741-7.
65. Peiro G, Diebold J, Baretton GB, Kimmig R, Lohrs U. Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome. Int J Gynecol Pathol 2001;20:359-67.
66. Takata T, Tanaka F, Yamada T, et al. Clinical significance of caspase-3 expression pathologic-stage I, nonsmall-cell lung cancer. Int J Cancer 2001;96(Suppl):54-60.
67. Chung TK, Cheung TH, Lo WK, et al. Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett 2002;180:63-8.
68. Giannopoulou I, Nakopoulou L, Zervas A, et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 2002;30:342-5.
69. Pingoud-Meier C, Lang D, Janss AJ, et al. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 2003;9:640-9.
70. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev Res 1995;34:91-109.
71. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents Cancer Res 1997;57:4285-300.
72. Mesner PW Jr, Bible KC, Martins LM, et al. Characterization of caspase processing and activation of HL-60 cell cytosol under cell-free conditions: nucleotide requirement and inhibitor profile. J Biol Chem 1999;274:22635-45.
73. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (Bethesda) 1991;83:757-66.
74. Kaufmann SH, McLaughlin SJ, Kastan M, Liu LF, Karp JE, Burke PJ. topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991;51:3534-43.
75. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
76. Kaufmann SH. Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 2001;296:283-6.
77. Kaufmann SH, Ewing CM, Shaper JH. The erasable Western blot. Anal Biochem 1987;161:89-95.
78. Martins LM, Mesner PW, Kottke TJ, et al. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood 1997;90:4283-96.
79. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science (Wash DC) 2002;296:550-53.
80. Hu Y, Benedict MA, Ding L, Nunez G. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J 1999;18:3586-95.
81. Walke DW, Morgan JI. A comparison of the expression and properties of Apaf-1 and Apaf-IL. Brain Res 2000;886:73-81.
82. Seol DW, Billiar TR. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem 1999;274:2072-6.
83. Srinivasula SM, Ahmad M, Guo Y, et al. Identification of an endogenous dominant-negative short isoform of caspase-98 that can regulate apoptosis. Cancer Res 1999;59:999-1002.
84. Angelastro JM, Moon NY, Liu DX, Yang AS, Greene LA, Franke TF. Characterization of a novel isoform of caspase-9 that inhibits apoptosis. J Biol Chem 2001;276:12190-200.
85. Scaffidi C, Medema JP, Krammer PH, Peter ME. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem 1997;272:26953-8.
86. Martins LM, Kottke TJ, Mesner PW, et al. Activation of multiple interleukin-1b converting enzyme homologues in cytosol and nuclei of HL-60 human leukemia cell lines during etoposide-induced apoptosis. J Biol Chem 1997;272:7421-30.
87. Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J 1997;16:2271-81.
88. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 1998;12:806-19.
89. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999;144:281-22.
90. Bergeron L, Perez GI, Macdonald G, et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 1998;12:1304-14.
91. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 2002;277:29803-9.
92. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-a-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science (Wash DC) 1997;278:1630-2.
93. Micheau O, Hammann A, Solary E, Dimanche-Boitrel MT. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun 1999;256:603-7.
94. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21:33-7.
95. Wu L, Smythe AM, Stinson SF, et al. Multidrug-resistant Phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 1992;52:3029-34.
96. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-10.
97. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 1998;58:4561-6.
98. Svingen PA, Tefferi A, Kottke TJ, et al. Effects of the Bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000;6:237-49.
99. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and BID proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000;60:1645-53.
100. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 2000;275:29-34.
101. Jia L, Srinivasula SM, Liu, F-T, et al. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 2001;98:414-21.
102. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304-13.
103. Belmokhtar CA, Hillion J, Dudognon C, et al. Apoptosome-independent pathway for apoptosis. Biochemical analysis of APAF-1 defects and biological outcomes. J Biol Chem 2003;278:29571-80.
104. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
105. Koomagi R, Volm M. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Anticancer Res 2000;20:493-6.
106. Janicke RU, Ng P, Sprengart ML, Porter AG. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 1998;273:15540-5.
107. Huang Y, Ray S, Reed JC, et al. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits Taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997;42:73-81.
108. MacFarlane M, Merrison W, Dinsdale D, Cohen GM. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol 2000;148:1239-54.
109. 2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 2002;277:1599-606.
110. Sane At, Bertrand R. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. Cancer Res 1999;59:3565-9.
111. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-33.
112. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996;93:14559-63.
113. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705-11.
114. Scott CL, Schuler M, Marsden VS, et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J Cell Biol 2004;164:89-96.